Latest information by the Dutch Government if your business in the Netherlands is impacted by COVID-19.Learn More

Alnylam Pharmaceuticals Expands Operations in the Netherlands

Decision by the leading RNAi therapeutic company marks latest proof of cutting-edge life sciences hub in the Netherlands

Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced the opening of its new office in Amsterdam. The decision reflects Alnylam’s belief in the combination of talent, infrastructure, R&D ecosystem and world class academic hospitals offered by Amsterdam and The Netherlands. It also recognizes the Netherlands as an open, collaborative environment in which highly innovative businesses can thrive.

The Netherlands will become a growing hub of Alnylam’s European activities, with major investments in technical operations, supply chain and finance activities, including partnerships with local companies. The Netherlands will also continue to be home to several Phase 3 clinical trial sites across Alnylam’s late-stage assets.

Dense and innovative life sciences ecosystem

With over 2,900 life sciences and health companies representing 34,000 jobs within a 200km radius, the Netherlands boasts one of the most concentrated and innovative life sciences ecosystems in the world. The global leader for patent applications in the area of medical technologies, its innovative potential is fueled by world-class health and research institutes, including 12 research universities, 85 hospitals including 7 University Medical Centers and more than 200 public-private partnerships between science, industry and government. The country is also a global digital health leader, ranking number 1 in the world in terms of adoption of eHealth solutions in hospitals and clinics.

Future hub of European operations

Barry Greene, President, Alnylam Pharmaceuticals, said: “We are thrilled with our growing presence in the Netherlands, with scientific, medical, technical operations and commercial excellence. We have identified the Netherlands as a future hub of our European operations. This is testimony to the country’s vibrant biotech ecosystem and to its attractive environment, which makes it possible for companies with groundbreaking innovation to flourish. We are grateful to our partners amsterdam inbusiness, Health~Holland and Invest in Holland Network as well as to the City of Amsterdam, for supporting Alnylam with enthusiasm and determination at every step of the journey”.

Source: Alnylam

31 October 2018

Get In Touch

Contact Us